English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Background  Marbofloxacin is a third-generation fluoroquinolone developed solely for veterinary medicine with a broad spectrum of antibacterial activity against some Gram-positive and most Gram-negative bacteria, including the bovine respiratory tract pathogen,  Pasteurella multocida . The objective of our study was to elucidate the pharmacokinetics and pharmacodynamics of marbofloxacin in a  Pasteurella multocida  infected murine lung model, and to estimate the magnitudes of pharmacokinetics-pharmacodynamics parameters associated with various effects.    Results  The pharmacokinetic studies revealed marbofloxacin kinetics in infected mice were linear over a dose ranging from 1.25 to 10 mg/kg of body weight. The protein binding in the plasma of neutropenic infected mice was 29.77 %. The magnitudes of the ratio of the free-drug area under the concentration-time curve over 24 h to MIC ( f AUC 0-24h /MIC) associated with static effect, a 2 log 10  reduction and a 3 log 10  reduction of bacterial counts were 40.84, 139.34, and 278.08 h, respectively.    Conclusions  Based on the dose range study, marbofloxacin exhibited concentration-dependent killing and the  f AUC/MIC was the PK/PD index that correlated best with efficacy (R 2  = 83 %). On the basis of a bactericidal effect goal of  f AUC 0-24h /MIC of 278.08 h, if marbofloxacin is used for the treatment of  P. multocida  serious lung infection with an MIC 90  of 0.12 μg/ml, the current dose (2 mg/kg) would fail to achieve a bactericidal effect. It would benefit from higher doses (4 ~ 6 mg/kg) than those commonly used in clinical practice.    Electronic supplementary material  The online version of this article (doi:10.1186/s12917-015-0608-1) contains supplementary material, which is available to authorized users.

Pharmacokinetics/pharmacodynamics of marbofloxacin in a Pasteurella multocida serious murine lung infection model